



# Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
(NOVELIX | 536565 | INE314I01036)

Date: 27<sup>th</sup> May, 2025

To,  
**The Deputy Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**Phiroze Jeejeebhoy Towers,**  
**Dalal Street, Fort,**  
**Mumbai-400001.**

**Sub: Submission of Audited Standalone Financial Results for the quarter and the year ended 31<sup>st</sup> March, 2025 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Ref: Scrip Code: 536565**

**Scrip Id: NOVELIX**

---

Respected Sir/ Madam,

Pursuant to the Regulation 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015 (Listing Regulations), the Board of Directors at their meeting held on 27<sup>th</sup> May, 2025 have considered and approved, the Audited standalone Financial Results of the company for the quarter and year ended 31<sup>st</sup> March, 2025 along with the report of the auditors thereon.

The Auditors' Report with an unmodified opinion on the said financial results is also attached herewith.


The Board Meeting commenced at 05:00 p.m. (IST) and concluded at 05:30 p.m. (IST).

The aforesaid information is also available on the website of the Company [www.trimurthidrugs.com](http://www.trimurthidrugs.com)  
We request you to take the aforesaid information on record for dissemination through your website.

Thanking you,

Yours Faithfully,

**For Novelix Pharmaceuticals Limited**



**Venkateshwarlu Pulluru**  
(Whole-time director)

**DIN: 02076871**

## Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)  
[www.trimurthidrugs.com](http://www.trimurthidrugs.com)



**CVS. Balachandra Rao & Co.,**  
Chartered Accountants

D.No:3-6-108/1, Flat No:203  
Sanatana Eternal, Street No:19  
Himayat Nagar  
Hyderabad - 500029.  
① 9849035315  
✉ cacvbsbala@gmail.com  
cvbsbala67@gmail.com

---

**Independent Auditor's Report on Audited standalone Quarterly Financial Results and Year to Date Results of Novelix Pharmaceuticals Limited (formerly known as Trimurthi Limited) CIN: L67120TG1994PLC018956, pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To

The Board of Directors of  
Novelix Pharmaceuticals Limited  
(Formerly Known as Trimurthi Limited)  
H No: 3-6-237/610, Flat No: 610, 6<sup>Th</sup> Floor,  
Lingapur LA Builders formerly known as Amrutha Estates,  
Himayat Nagar, Hyderabad, Telangana- 500029.

**Report on the audit of Standalone Financial Results**

**Opinion**

We have audited the accompanying standalone quarterly financial results of Novelix Pharmaceuticals Limited (Formerly Known as Trimurthi Limited) for the quarter ended 31<sup>st</sup> March 2025 and the year ended 31<sup>st</sup> March 2025 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“LODR Regulations”).

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit/loss and other comprehensive income and other financial information for the quarter ended March 31, 2025 as well as the year ended as on March 31, 2025.

  
CVS. Balachandra Rao & Co.,  
Chartered Accountants

## **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our opinion is not modified in respect of this matter.

## **Management's Responsibilities for the Standalone Financial Results**

The Statement has been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the Company's financial reporting process.



## **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### **Other Matter**

The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review as required under the Listing Regulations.

As per our report of even date,  
For CVS Balachandra Rao & Co  
Chartered Accountants  
Firm Regd. No: 007507S





CVS Balachandra Rao  
Partner  
Membership No.204580  
UDIN: 25204580BMHZGH5906  
Date: 27-05-2025  
Place: Hyderabad



# Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
(NOVELIX | 536565 | INE314I01036)


## Statement of Audited Standalone Financial Results for the quarter and year ended 31<sup>st</sup> March, 2025

(Rs. In Lakhs except Earnings per share)

S. No	Particulars	3 Months Ended	Preceding 3 Months ended	Corresponding 3 Months Ended in Previous Year	Year to Date Figures for Current Period Ended	Year to date figures for Previous year ended
		31.03.2025	31.12.2024	31.03.2024	31.03.2025	31.03.2024
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	<b>Revenue</b>					
	a) From operations	2,086.10	529.98	84.29	3,071.85	422.38
	b) Other Income (Refer to Note No.3)	(0.00)	0.11	12.92	1.59	30.74
	<b>Total Revenue</b>	<b>2,086.10</b>	<b>530.09</b>	<b>97.21</b>	<b>3,073.44</b>	<b>453.12</b>
2	<b>Expenses</b>					
	(a) Cost of Material Consumed	2,021.61	561.14	74.85	2,922.25	421.02
	(b) Purchases of stock-in- trade					
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	6.77	(58.95)	(18.33)	35.12	(37.39)
	(d) Employees Benefits expenses	0.73	0.78	3.17	6.86	15.43
	(e) Finance Cost	-	-	-	-	-
	(f) Depreciation amortization expenses	2.34	0.49	0.61	3.80	3.81
	(g) Other Expenses	33.59	13.84	9.11	93.08	48.11
	<b>Total Expenses</b>	<b>2,065.04</b>	<b>517.29</b>	<b>69.42</b>	<b>3,061.11</b>	<b>450.99</b>
3	<b>Profit from ordinary activities before exceptional Items (1 - 2)</b>	21.06	12.80	27.79	12.33	2.13
4	<b>Exceptional Items - Income/ (Expenses)</b>					
5	<b>Profit from ordinary activities before tax (3 - 4)</b>	21.06	12.80	27.79	12.33	2.13
6	<b>Tax Expenses</b>					
	(a) Current Tax	2.96	-	-	2.96	
	(b) Deferred Tax	(0.15)	(1.99)	0.12	0.92	1.08
7	<b>Profit/(Loss) for the period (5 -6)</b>	18.25	14.79	27.66	8.45	1.04
8	A (i) Items that will not be reclassified to profit or loss (net of tax)					
	(ii) Income Tax relating to items that will not be reclassified to profit or loss					

Novelix Pharmaceuticals limited  
(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat  
Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)  
[www.trimurthidrugs.com](http://www.trimurthidrugs.com)



Venkatal



# Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
(NOVELIX | 536565 | INE314I01036)


	B (i) Items that will not be reclassified to profit or loss (net of tax)	-	-	(0.31)	-	14.92
	(ii) Income Tax relating to items that will not be reclassified to profit or loss					
9	Total Comprehensive Income, net of tax (7 + 8)	18.25	14.79	27.36	8.45	15.97
10	Paid up equity share capital (Face Value of Rs.10/- each)	995.0	995.0	810.0	995.0	810.0
11	Earnings per share (of Rs.10/-each) not annualised)					
	(a) Basic	0.183	0.150	0.340	0.085	0.013
	(b) Diluted	0.199	0.160	0.340	0.092	0.013

See accompanying notes to financial results

**NOTES:**

1	The above audited Financial Results of the company for the quarter and year ended March 31, 2025 have been reviewed by the Audit Committee and on its recommendation, have been approved by the Board of Directors at its meeting held on 27 <sup>th</sup> May, 2025.
2	The Company has Multiple business segments i.e. 1. 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). 2. Investment in Shares 3. Trading in shares 4. Foods 5. Finance.
3	Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.
4	These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016.
5	The Company has opted to publish the financial result. The standalone results of the company will be available on the company's website <a href="http://www.trimurthidrugs.com">www.trimurthidrugs.com</a>

By the order of the Board  
For Novelix Pharmaceuticals Limited



Venkateshwarlu Pulluru

(Whole-time director)

DIN: 02076871

Date: 27/05/2025

Place: Hyderabad

## Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)

[www.trimurthidrugs.com](http://www.trimurthidrugs.com)




**Novelix Pharmaceuticals limited**  
 (Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
 (NOVELIX | 536565 | INE314I01036)

**Segment Reporting**

(Amount in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31.03.2025 (Audited)	31.12.2024 (Unaudited)	31.03.2024 (Audited)	31.03.2025 (Audited)	31.03.2024 (Audited)
1	Segment Revenue					
	a. Pharma Business	2086.10	529.98	3.58	2950.95	14.51
	b. Investment in Shares	--	--	6.50	109.19	6.65
	c. Trading in shares	--	--	80.71		411.52
	d. Foods	--	--	--	--	--
	e. Finance		0.11	6.42	13.31	20.44
	Total Segment Revenue	2086.10	530.09	97.21	3073.44	453.12
	Less: Inter Segment Revenue	--	--	--	--	--
	Revenue From Operations	2086.10	530.09	97.21	3073.44	453.12
2	Segment Result					
	Profit (+)/ Loss (-) before tax and interest from each segment					
	a. Pharma Business	21.06	12.80	3.07	25.44	2.05
	b. Investment in Shares			6.50		6.65
	c. Trading in shares			11.79	-14.70	-27.01
	d. Foods					
	e. Finance			6.42	1.60	20.44
	Total Profit before tax	21.06	12.80	27.78	12.33	2.13
	Less:					
	i. Interest	--	--	---	--	--
	ii. Other Un-allocable expenses net off	--	--	---	--	--
	iii. Un-allocable income	--	--	---	--	--
	Total Profit Before Tax	21.06	12.80	27.78	12.33	2.13

*Venkata*



**Novelix Pharmaceuticals limited**

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)  
[www.trimurthidrugs.com](http://www.trimurthidrugs.com)



**Novelix Pharmaceuticals limited**  
 (Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
 (NOVELIX | 536565 | INE314I01036)

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31.03.2025	31.12.2024	31.03.2024	31.03.2025	31.03.2024
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
3	Capital Employed					
	a. Pharma Business	1753.93	897.56	32.46	1753.93	32.46
	b. Investment in Shares	--	--	306.37	--	306.37
	c. Trading in shares	--	--	396.64	--	396.64
	d. Foods	--	--	--	--	--
	e. Finance	--	--	--	--	--
	Total	1753.93	897.56	735.47	1753.93	735.47

By the order of the Board  
 For Novelix Pharmaceuticals Limited



Venkateshwarlu Pulluru  
 (Whole-time director)  
 DIN: 02076871  
 Date: 27/05/2025  
 Place: Hyderabad

**Novelix Pharmaceuticals limited**

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)  
[www.trimurthidrugs.com](http://www.trimurthidrugs.com)



**Novelix Pharmaceuticals limited**  
 (Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
 (NOVELIX | 536565 | INE314I01036)

STATEMENT OF ASSETS AND LIABILITIES AS AT MARCH 31, 2025

PARTICULARS		(Rs. In Lakhs)	
		As at 31-March 2025 (Audited)	As at 31-March 2024 (Audited)
<b>ASSETS</b>			
<b>1</b>	<b>Non - current assets</b>		
(a)	Property, plant and equipment	18.57	11.76
(b)	Capital work in progress	-	-
(c)	Investment property	-	-
(d)	Intangible assets	0.00	0.00
(e)	Financial assets	-	-
	(i) Investments	4.32	306.37
	(ii) Loans	-	-
	(iii) Other financial assets	-	-
(f)	Deferred tax Assets (Net)	4.46	5.38
(g)	Other non-current assets	-	-
	<b>Total non-current assets</b>	<b>27.35</b>	<b>323.51</b>
<b>2</b>	<b>Current assets</b>		
(a)	Inventories	84.32	119.45
(b)	<b>Financial assets</b>		
	(i) Investments	-	-
	(ii) Trade receivables	1,813.69	1.34
	(iii) Cash and cash equivalents	67.86	11.78
	(iv) Other balances with banks	-	-
	(v) Loans	-	-
	(vi) Other financial assets	702.31	-
(c)	Other Current assets	25.11	280.42
	<b>Total current assets</b>	<b>2693.29</b>	<b>412.98</b>
	<b>TOTAL ASSETS</b>	<b>2720.64</b>	<b>736.49</b>
<b>EQUITY AND LIABILITIES</b>			
<b>1</b>	<b>Equity</b>		
(a)	Share capital	995.00	810.00
(b)	Other equity	758.93	(74.52)
	<b>Total Equity</b>	<b>1753.93</b>	<b>735.48</b>
<b>2</b>	<b>Non-current liabilities</b>		
(a)	Financial liabilities	-	-
	(i) Long-term borrowings	-	-
	(ii) Deferred tax liabilities (net)	-	-
	(iii) Other financial liabilities	-	-
(b)	Provisions	-	-
(c)	Other non-current liabilities	-	-
	<b>Total non-current liabilities</b>	<b>0.00</b>	
<b>3</b>	<b>Current liabilities</b>		
(a)	Financial liabilities	-	-
	(i) Borrowings	-	-


**Novelix Pharmaceuticals limited**

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)

[www.trimurthidrugs.com](http://www.trimurthidrugs.com)

*Venkata*





# Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
(NOVELIX | 536565 | INE314I01036)

	(ii) Trade payables	930.11	0.30
	(iii) Other financial liabilities	-	-
(b)	Provisions	36.60	0.71
(c)	Other current Liabilities	-	-
	<b>Total current liabilities</b>	<b>966.72</b>	<b>1.01</b>
	<b>Total Liabilities</b>	<b>966.72</b>	<b>1.01</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>2720.64</b>	<b>736.49</b>

By the order of the Board  
For Novelix Pharmaceuticals Limited



Venkateshwarlu Pulluru  
(Whole-time director)  
DIN: 02076871  
Date: 27/05/2025  
Place: Hyderabad

# Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)  
[www.trimurthidrugs.com](http://www.trimurthidrugs.com)



**Novelix Pharmaceuticals limited**  
 (Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
 (NOVELIX | 536565 | INE314I01036)

**CASH FLOW STATEMENT FOR THE PERIOD ENDED 31ST MARCH 2025**

(Amounts in Lakhs)

Particulars	As at 31-03-2025	As at 31-03-2024
<b>A. Cash Flow from Operating Activities:</b>		
Net Profit before Tax and Extraordinary Items	12.33	2.13
Adjustments for:		
Depreciation	3.80	3.81
Interest & Other Income	(1.59)	(30.74)
Loss on Sale of Fixed Assets		
Loss on Sale of Investments & Property		
Profit on sale of mutual funds		
Operating profit before Working Capital Changes	14.54	(24.80)
Adjustments for:		
Trade and Other receivables	(2,259.35)	32.99
Inventories	35.12	(37.39)
Trade & Other payables	841.24	(5.15)
Cash generated from Operations	(1,382.99)	(9.55)
<b>Cash flow before Extraordinary Items</b>	<b>(1,368.45)</b>	<b>(34.35)</b>
Extraordinary Items and Tax		
<b>Net Cash used for Operating activities</b>	<b>(1,368.45)</b>	<b>(34.35)</b>
<b>B. Cash Flow from Investing Activities:</b>		
Purchase of Fixed Assets	(10.61)	
Sale of Fixed Assets		1.85
Capital Work in progress		
Sale of Investments	302.05	(13.93)
Increase / (Decrease) in Security Deposits		30.74
Interest & Other Income	1.60	
<b>Net Cash flow from Investing activities</b>	<b>293.04</b>	<b>18.65</b>
<b>C. Cash Flow from Financing Activities:</b>		
Increase in Share Capital	185.00	
Increase in Share Premium	121.50	
Increase / Decrease in Long Term Borrowings		
Share Issue and Preliminary Expenses	-	
Warrants Issued	825.00	
<b>Net Cash flow from Financing activities</b>	<b>1,131.50</b>	<b>-</b>
<b>Net Increase in Cash and Cash Equivalents (A+B+C)</b>	<b>56.08</b>	<b>(15.68)</b>
Cash and Cash Equivalents as at (Opening Balance)	11.79	27.47
Cash and Cash Equivalents as at (Closing Balance)	67.87	11.79

By the order of the Board

For Novelix Pharmaceuticals Limited

  
 Venkateshwarlu Poluru  
 (Whole-time director)  
 DIN: 02076871  
 Date: 27/05/2025  
 Place: Hyderabad



**Novelix Pharmaceuticals limited**

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)  
[www.trimurthidrugs.com](http://www.trimurthidrugs.com)